C68.F Crescent Biopharma, Inc.
- Market cap
- EUR 468M
- P/E
- -
- P/B
- 2.98x
- ROE
- -59.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is C68.F undervalued?
Graham numberThe Graham number of Crescent Biopharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Crescent Biopharma, Inc. fundamental analysis
No fundamental analysis for Crescent Biopharma, Inc. yet.
Crescent Biopharma, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly k…
Full company profileCrescent Biopharma, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Crescent Biopharma, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2025 | 2026 Anlz |
|---|---|---|
| Income Statement | ||
| Revenue | 10.8M | 2.08M |
| Operating Income | -153M | -102M |
| EBITDA | -150M | -96.0M |
| Net Income | -154M | -96.2M |
| EPS | -5.06 | -3.47 |
| Balance Sheet | ||
| Total Assets | 240M | 183M |
| Total Liabilities | 37.3M | 19.5M |
| Shareholders' Equity | 203M | 163M |
| Cash & Short-term Investments | 213M | 172M |
| Cash Flow | ||
| Operating Cash Flow | -71.5M | -56.8M |
| Capital Expenditure | 72.9M | 16.3M |
| Free Cash Flow | -144M | -73.1M |
| Ratios | ||
| ROE | -75.8% | -59.0% |
| ROA | -64.1% | -52.7% |
| Net Profit Margin | -1,419.6% | -4,631.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Crescent Biopharma, Inc. dividends
Crescent Biopharma, Inc. has not paid dividends in the last 1 fiscal years.
Who owns Crescent Biopharma, Inc.
- Insiders 0.27%
- Institutions 88.88%
- Public & others 10.86%
- Shares outstanding 37.1M
- Free float 27.0M
Crescent Biopharma, Inc. company profile
- Company name
- Crescent Biopharma, Inc.
- Ticker
- C68.F
- ISIN
- KYG2545C1042
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 300 Fifth Avenue, Waltham, MA, United States, 02451
- Phone
- 617 430 5595
- Website
- crescentbiopharma.com
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Crescent Biopharma, Inc. management
10- Mr. Joshua T. BrummCEO & Director · born 1978
- Dr. Jonathan McNeill M.D.President & COO · born 1985
- Dr. Ellie Im M.D.Chief Medical Officer · born 1978
- Mr. Richard William Scalzo M.B.A.Chief Financial Officer · born 1986
- Mr. Ryan LynchSenior VP of Finance, Treasurer & Chief Accounting Officer · born 1984
- Dr. Wenjie Cheng Ph.D.Senior Vice President of Technical Operations
- Dr. Jan Pinkas Ph.D.Chief Scientific Officer · born 1969
- Ms. Barbara Bispham Hale J.D.General Counsel & Corporate Secretary · born 1987
- Ms. Amy ReillyChief Communications Officer · born 1974
- Mr. Christopher DoughtyChief Business Officer · born 1988